KITAIbodies®
Our KITAIbodies® technology is built on a modular engineering architecture that transforms into a scalable therapeutic platform:
- One core domain – multiple therapeutic formats to accelerate new programs
- Rapid adaptability across indications
- Ready for clinical drug development with partners
Therapeutic drugs incorporating the KITAIbodies® have a clear potential for integration into both first line therapy and standard of care. KITAIbodies® are developed from the evolutionary unique Alpaca antibodies known for their superior properties and ability to penetrate the tumor.
Step by step
How KITAIbodies® work
Superior drug properties
The KITAIbodies® are developed from the evolutionary unique Alpaca antibodies known for their superior properties
Block HVEM signaling
Inside the tumor, KITAIbodies® bind and block HVEM — shutting down the signaling that fuels growth and helps the tumor evade the immune system.
Halt growth and invasion
By disrupting this pathway, the therapy suppresses tumor proliferation and invasion — turning an aggressive disease into a treatable target.